Chemokine containing apheresis column and methods of use
An apheresis column loaded with a solid support comprises one or more chemokines, in particular biotinylated chemokines, immobilized directly or indirectly on the support, in particular on a support carrying streptavidin. Also disclosed are uses of the column and the support and a method of depleting cells, in particular leukocytes, from the peripheral blood of a person suffering from an inflammatory condition such as Inflammatory Bowel Disease (IBD).
1. An apheresis column loaded with a solid support comprising one or more chemokines immobilized directly or indirectly on the support to permit removal of a cell expressing the cognate receptor of the one or more chemokines from the peripheral blood of a subject.
2. The column of claim 1 , wherein said one or more chemokines are biotinylated and wherein the support comprises streptavidin immobilized thereon and wherein the one or more biotinylated chemokines are bound to the streptavidin on the support.
3. The column of claim 1 , wherein the support comprises a carbohydrate having a molecular weight of more than 100 kDa, optionally cross-linked.
4. The column of claim 1 , wherein the one or more chemokines is selected from the group consisting of CCL25, MIP-Ia, MIP-Ib, MCP-I, MCP-2, MCP-3, MCP-4, TARC, MDC, MIP-3, MIP-3a, MIP3b, MIP-4, 1-309, HCC-I, HCC-2, SLC, IL-8, GROa, GROb, GROg, RANTES, NAP-2, ENA78, GCP-2, IP-IO, MIG, I-TAC, SDF, fractalkine, lymphotactin, eotaxin, eotaxin-2, 1-309, and BLC.
5. The column of claim 4 , wherein the one or more chemokines is CCL25.
6. The column of claim 1 , wherein the support comprises spheres, beads, or particles of irregular form having an average size from 50 μm to 2 mm.
7. The column of claim 1 , wherein the support is treated with an agent to provide the support with anti-coagulation properties.
8. An apheresis column, comprising:
a solid support comprising streptavidin immobilized thereon; and
truncated CCL25 chemokine comprising an amino acid sequence 95% identical to the sequence set forth as SEQ ID NO: 1, wherein the truncated CCL25 chemokine is biotinylated to permit immobilization of the CCL25 chemokine on the solid support.
9. The column of claim 8 , wherein the truncated CCL25 chemokine is biotinylated at position 72 (lysine) to permit immobilization of the chemokine on a solid support.
10. A method of removing one or more cells expressing a cognate receptor of one or more chemokines from the peripheral blood of a subject, comprising:
providing the apheresis column of claim 1 ; and,
contacting the column with a portion of the subject's peripheral blood, thereby depleting the portion of the subject's peripheral blood of at least one cell expressing a cognate receptor of the one or more chemokines.
11. The method of claim 10 , further comprising infusing the depleted blood to the subject.
12. The method of claim 10 , wherein the cell is a leukocyte selected from the group consisting of a T lymphocyte, monocyte, neutrophil granulocyte, and an eosinophil granulocyte.
13. The method of claim 10 , wherein removing one or more cells expressing a cognate receptor of one or more chemokines from the peripheral blood of a subject is used to treat an inflammatory condition.
14. The method of claim 10 , wherein the one or more chemokine is selected from the group consisting of CCL25, MIP-Ia, MIP-Ib, MCP-I, MCP-2, MCP-3, MCP-4, TARC, MDC, MIP-3, MIP-3a, MIP3b, MIP-4, 1-309, HCC-I, HCC-2, SLC, IL-8, GROa, GROb, GROg, RANTES, NAP-2, ENA78, GCP-2, IP-IO, MIG, I-TAC, SDF, fractalkine, lymphotactin, eotaxin, eotaxin-2, 1-309, and BLC.
15. The method of claim 14 , wherein the one or more chemokines is CCL25.
16. The method of claim 15 , wherein the chemokine is a truncated CCL25 chemokine comprising an amino acid sequence 95% identical to the amino acid sequence set forth as SEQ ID NO: 1.
17. The method of claim 16 , wherein truncated CCL25 chemokine is biotinylated at position 72 (lysine) to permit immobilization of the chemokine on a solid support.
18. The method of claim 10 , wherein the support has been treated with an agent to provide the support with anti-coagulation properties.
19. A method of removing one or more cells expressing a cognate receptor of one or more chemokines from the peripheral blood of a subject, comprising:
providing the apheresis column of claim 8 ; and
contacting the column with a portion of the subject's peripheral blood, thereby depleting the portion of the subject's peripheral blood of at least one cell expressing a cognate receptor of the one or more chemokines.
20. The method of claim 19 , wherein the support is a heparinized support.
21. The apheresis column of claim 8 , wherein the truncated CCL25 chemokine consists of the amino acid sequence set forth as SEQ ID NO: 1.